
Management ChangeJul 9, 2026, 08:03 AM
Vera Therapeutics Appoints Nancy Bowman as Chief Regulatory Officer
AI Summary
Vera Therapeutics, Inc. announced a change in its Chief Regulatory Officer role. William Turner will transition from his current position to Special Advisor for Regulatory Affairs, effective August 3, 2026. Nancy Bowman, M.D., Ph.D., will take over as the new Chief Regulatory Officer on the same date.
Key Highlights
- William Turner will transition from Chief Regulatory Officer to Special Advisor for Regulatory Affairs.
- Nancy Bowman, M.D., Ph.D., will succeed Mr. Turner as Chief Regulatory Officer.
- Both changes are effective as of August 3, 2026.
Price Impact
More from VERA
Quarterly ResultNov 5, 4:15 PM
Vera Therapeutics Q3 Revenue $10.3M; Net Loss $93.7M; TRUTAKNA Launch Underway
Business UpdateOct 20, 8:02 AM
Vera Therapeutics Announces Upcoming Investor Webcasts for Clinical Trial Results and Q3 Financials
Clinical TrialSep 15, 6:56 AM
Vera Therapeutics: TRUTAKNA Meets All Endpoints in IgAN Trial